Citadel Advisors’s TG Therapeutics TGTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.11M | Sell |
213,900
-171,900
| -45% | -$5.12M | ﹤0.01% | 3791 |
|
|
2025
Q4 | $11.5M | Buy |
385,800
+21,000
| +6% | +$686K | ﹤0.01% | 3077 |
|
|
2025
Q3 | $13.2M | Sell |
364,800
-33,600
| -8% | -$1.11M | ﹤0.01% | 2873 |
|
|
2025
Q2 | $14.3M | Sell |
398,400
-3,400
| -0.8% | -$127K | ﹤0.01% | 2571 |
|
|
2025
Q1 | $15.8M | Sell |
401,800
-143,400
| -26% | -$4.83M | ﹤0.01% | 2302 |
|
|
2024
Q4 | $16.4M | Buy |
545,200
+277,400
| +104% | +$7.96M | ﹤0.01% | 2390 |
|
|
2024
Q3 | $6.26M | Buy |
267,800
+18,700
| +8% | +$408K | ﹤0.01% | 3592 |
|
|
2024
Q2 | $4.43M | Sell |
249,100
-100,400
| -29% | -$1.6M | ﹤0.01% | 3944 |
|
|
2024
Q1 | $5.32M | Sell |
349,500
-308,100
| -47% | -$4.91M | ﹤0.01% | 3869 |
|
|
2023
Q4 | $11.2M | Buy |
657,600
+180,500
| +38% | +$2.1M | ﹤0.01% | 2688 |
|
|
2023
Q3 | $3.99M | Buy |
477,100
+83,000
| +21% | +$1.16M | ﹤0.01% | 4016 |
|
|
2023
Q2 | $9.79M | Buy |
394,100
+58,000
| +17% | +$1.5M | ﹤0.01% | 2704 |
|
|
2023
Q1 | $5.05M | Sell |
336,100
-283,300
| -46% | -$4.3M | ﹤0.01% | 3798 |
|
|
2022
Q4 | $7.33M | Buy |
619,400
+325,400
| +111% | +$2.36M | ﹤0.01% | 3258 |
|
|
2022
Q3 | $1.74M | Sell |
294,000
-74,100
| -20% | -$486K | ﹤0.01% | 5855 |
|
|
2022
Q2 | $1.56M | Sell |
368,100
-2,900
| -0.8% | -$18.1K | ﹤0.01% | 6057 |
|
|
2022
Q1 | $3.53M | Buy |
371,000
+222,400
| +150% | +$2.57M | ﹤0.01% | 4851 |
|
|
2021
Q4 | $2.82M | Buy |
148,600
+26,000
| +21% | +$675K | ﹤0.01% | 5457 |
|
|
2021
Q3 | $4.08M | Sell |
122,600
-35,700
| -23% | -$1.1M | ﹤0.01% | 4703 |
|
|
2021
Q2 | $6.14M | Buy |
158,300
+7,300
| +5% | +$287K | ﹤0.01% | 4006 |
|
|
2021
Q1 | $7.28M | Sell |
151,000
-158,200
| -51% | -$7.6M | ﹤0.01% | 3499 |
|
|
2020
Q4 | $16.1M | Buy |
309,200
+40,200
| +15% | +$1.36M | ﹤0.01% | 2050 |
|
|
2020
Q3 | $7.2M | Buy |
269,000
+52,500
| +24% | +$1.21M | ﹤0.01% | 2666 |
|
|
2020
Q2 | $4.22M | Buy |
216,500
+1,000
| +0.5% | +$16.1K | ﹤0.01% | 3323 |
|
|
2020
Q1 | $2.12M | Buy |
215,500
+127,400
| +145% | +$1.61M | ﹤0.01% | 4044 |
|
|
2019
Q4 | $978K | Buy |
88,100
+17,000
| +24% | +$129K | ﹤0.01% | 5608 |
|
|
2019
Q3 | $399K | Sell |
71,100
-6,200
| -8% | -$43.2K | ﹤0.01% | 7140 |
|
|
2019
Q2 | $669K | Sell |
77,300
-17,200
| -18% | -$130K | ﹤0.01% | 6351 |
|
|
2019
Q1 | $760K | Sell |
94,500
-70,200
| -43% | -$379K | ﹤0.01% | 6077 |
|
|
2018
Q4 | $675K | Sell |
164,700
-155,000
| -48% | -$770K | ﹤0.01% | 5942 |
|
|
2018
Q3 | $1.79M | Buy |
319,700
+217,600
| +213% | +$2.49M | ﹤0.01% | 4590 |
|
|
2018
Q2 | $1.34M | Sell |
102,100
-4,800
| -4% | -$66K | ﹤0.01% | 4724 |
|
|
2018
Q1 | $1.52M | Sell |
106,900
-9,900
| -8% | -$127K | ﹤0.01% | 4156 |
|
|
2017
Q4 | $958K | Buy |
116,800
+59,500
| +104% | +$520K | ﹤0.01% | 4718 |
|
|
2017
Q3 | $679K | Sell |
57,300
-56,800
| -50% | -$647K | ﹤0.01% | 4884 |
|
|
2017
Q2 | $1.15M | Buy |
114,100
+87,400
| +327% | +$978K | ﹤0.01% | 3892 |
|
|
2017
Q1 | $311K | Buy |
26,700
+15,600
| +141% | +$112K | ﹤0.01% | 5842 |
|
|
2016
Q4 | $52K | Buy |
+11,100
| New | +$65.1K | ﹤0.01% | 6860 |
|
|
2016
Q1 | – | Sell |
-4,300
| Closed | -$51K | – | 7944 |
|
|
2015
Q4 | $51K | Sell |
4,300
-11,100
| -72% | -$140K | ﹤0.01% | 7297 |
|
|
2015
Q3 | $155K | Buy |
15,400
+4,900
| +47% | +$73K | ﹤0.01% | 6470 |
|
|
2015
Q2 | $174K | Sell |
10,500
-5,100
| -33% | -$80.8K | ﹤0.01% | 6493 |
|
|
2015
Q1 | $241K | Buy |
15,600
+2,100
| +16% | +$31.8K | ﹤0.01% | 5946 |
|
|
2014
Q4 | $214K | Buy |
13,500
+7,000
| +108% | +$91.2K | ﹤0.01% | 5904 |
|
|
2014
Q3 | $69K | Sell |
6,500
-2,600
| -29% | -$24.1K | ﹤0.01% | 6682 |
|
|
2014
Q2 | $85K | Buy |
9,100
+5,000
| +122% | +$32K | ﹤0.01% | 6362 |
|
|
2014
Q1 | $28K | Sell |
4,100
-600
| -13% | -$3.55K | ﹤0.01% | 7134 |
|
|
2013
Q4 | $18K | Buy |
+4,700
| New | +$19K | ﹤0.01% | 6525 |
|
Other funds holding TGTX
VPM
VCM
SCM
CAM
Citadel Advisors's TGTX Position: Q1 2026 in Review
Citadel Advisors increased its TG Therapeutics (TGTX) stake by 90% in Q1 2026, buying an estimated $27.2M and bringing the position to 1,922,889 shares worth $63.9M. The position accounts for 0.01% of the portfolio, ranked #1140.
Citadel Advisors first reported a position in TGTX in Q4 2013 and has held it in 48 quarters since. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.
- Citadel Advisors held 1,922,889 shares of TG Therapeutics worth $63.9M as of Q1 2026.
- Citadel Advisors bought 911,852 TG Therapeutics shares in Q1 2026, an estimated $27.2M.
- TG Therapeutics made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1140 holding.
- Citadel Advisors first reported a position in TG Therapeutics in Q4 2013 and has held it in 48 quarters since.
- 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.